Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMB 051

Drug Profile

AMB 051

Alternative Names: AMB 053; AMB-051; AMB-055; AMB-05X; AMG-820

Latest Information Update: 07 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; AmMax Bio; LifeMax Laboratories
  • Class Antibodies; Antifibrotics; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Giant cell tumour of tendon sheath; Idiopathic pulmonary fibrosis
  • Phase I/II Solid tumours
  • Preclinical Autosomal recessive polycystic kidney disease; Diabetic macular oedema; Unspecified; Wet age-related macular degeneration

Most Recent Events

  • 24 May 2024 AmMax Bio terminates a phase II trial in Giant cell tumour of tendon sheath in Germany, Hungary, Poland, Ukraine, Netherlands, Czech Republic (IV) (NCT04938180) (EudraCT2020-004870-22)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Giant-cell-tumour-of-tendon-sheath in USA (IV)
  • 30 Jan 2023 AmMax Bio plans a phase III trial for Tenosynovial Giant Cell Tumor
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top